Generally, complete functional recovery in 75% to 80% of CVT patients has been reported when timely intervened. However, about 15% mortality and/or disability have been noted [10]. Risk factors like infections, malignancy, confusion or coma, intracranial hemorrhage, deep vein involvement, age, and gender (male) influence the outcomes of the treatment [10, 11]. Predominantly, anticoagulation is the first choice of treatment in CVT patients to prevent thrombus progression, thereby reducing the further complications of pulmonary embolus [15]. In severe cases or in cases where anticoagulation does not produce positive results, endovascular thrombolysis or mechanical thrombectomy become the choice of treatment [15].

A standard embolic agent is characterized or defined by its versatility of use, controllable chemical and physical properties for simplicity of application, ability to be monitored via X-ray fluoroscopy imaging, and predictability and assurance in terms of embolization rate and delivery distance  [16]. The most commonly used agents are ethanol based (e.g., Ethibloc) or absolute ethanol, which can be used percutaneously or via catheter delivery system [8]. The drawback of ethanol is its anesthetic effect and pain for patients. The second most common agent is Lipiodol (Guerbet LLC, France), which is a mixture of iodinated poppy seed ethyl esters generally used for imaging of hepatocarcinomas [8]. Due to its high viscosity and prolonged vasculature clearance, its suitability for the treatment, as transarterial chemoembolization is preferred. Of late, the novel non-adhesive liquid embolic agent Menox LES, comprised of EVOH copolymer dissolved in DMSO has demonstrated its feasibility in the treatment of cerebral AVMs [12]. Menox LES has been presented in 3 different viscosities, Menox LES 18 (18 cSt viscosity) (5% EVOH), Menox LES 20 (20 cSt viscosity) (6% EVOH) and Menox LES (34 cSt viscosity) (7% EVOH) [17]. The initial study report of Menox LES by Sirakov S et al. in 2019 [12] established Menox LES as having comparable results with well-established products Onyx (eV3-Covedien, Irvine, California, USA), Squid (Balt Extrusion, Montmorency, France) and PHIL (Microvention Inc, California, USA) [12]. In the reported study, 58.3% of the treated patients demonstrated curative embolization and partial embolization was reported in 42.6% of the patients. [12]. Another study was conducted to investigate the efficacy of using Menox LES in conjunction with PHIL through the same microcatheter for the endovascular embolization of cerebral AVMs. The average reduction in treated AVM size was 85%, ranging from 50%-100% while achieving 62.5% (10/16) complete embolization. There was no mortality or clinical follow-up worsening in the cases [14]. In the present case report, a similar outcome was observed where no procedural complications were seen and ease of use of Menox LES was also demonstrated. Slow infusion was achieved due to its lower viscosity and successful embolization of CVT was achieved.